News | July 21, 2022
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
Advancing to IND-enabling studies with multiple drug candidates
Philips demonstrates portfolio of smart connected imaging systems and integrated radiology workflow solutions designed to improve diagnostic confidence and clinical outcomes
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
VACUUBRAND has evolved rapidly in recent years, developing new innovative vacuum technology for laboratories, research and engineering
Subscribe To Our Newsletter & Stay Updated
